Flag of the European Union EU Clinical Trials Register Help

Clinical trials for prostate cancer

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44341   clinical trials with a EudraCT protocol, of which   7370   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    815 result(s) found for: prostate cancer. Displaying page 2 of 41.
    « Previous 1  2  3  4  5  6  7  8  9  Next» Last»»
    EudraCT Number: 2006-006913-34 Sponsor Protocol Number: FE200486 CS21A Start Date*: 2007-03-23
    Sponsor Name:Ferring Pharmaceuticals A/S
    Full Title: An Open-Label, Multi-Centre, Extension Study, Evaluating the Long-Term Safety and Tolerability of Degarelix One-Month Dosing Regimen in Patients with Prostate Cancer Requiring Androgen Ablation The...
    Medical condition: Patients with histologically proven prostate cancer of all stages in whom endocrine treatment is indicated.
    Disease: Version SOC Term Classification Code Term Level
    9.1 10060862 Prostate cancer LLT
    Population Age: Adults, Elderly Gender: Male
    Trial protocol: HU (Completed) NL (Completed) DE (Completed) CZ (Completed) GB (Completed)
    Trial results: View results
    EudraCT Number: 2004-003814-40 Sponsor Protocol Number: FE200486 CS12A Start Date*: 2005-02-01
    Sponsor Name:Ferring Pharmaceuticals A/S
    Full Title: An open-label, multi-centre, extension study evaluation the long-term safety and tolerability of Degarelix one-month depots in patients with prostate cancer
    Medical condition: Prostate Cancer
    Disease: Version SOC Term Classification Code Term Level
    7.0 10060862 pr t
    Population Age: Adults, Elderly Gender: Male
    Trial protocol: HU (Completed) DE (Completed)
    Trial results: View results
    EudraCT Number: 2022-002571-11 Sponsor Protocol Number: ENHANCE Start Date*: 2022-11-25
    Sponsor Name:Institut Mutualiste Montsouris
    Full Title: EvaluatioN of High-Intensity Focused Ultrasound (HIFU) Hemi-ablation and short-term AndrogeN deprivation therapy Combination to Enhance prostate control for intermediate risk localized prostate can...
    Medical condition: Intermediate risk localized prostate cancer
    Disease: Version SOC Term Classification Code Term Level
    21.0 100000004864 10036946 Prostatic cancer LLT
    Population Age: Adults, Elderly Gender: Male
    Trial protocol: FR (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2006-004572-13 Sponsor Protocol Number: ARD-0301-010 Start Date*: 2006-11-06
    Sponsor Name:Ardana Bioscience Ltd
    Full Title: A Phase II multi-centre, randomized, open-label study investigating the pharmacokinetics, pharmacodynamics, efficacy and safety of two loading dose regimens of a new GnRH antagonist, Teverelix, lon...
    Medical condition: Locally advanced and/or metatstatic prostate cancer
    Disease: Version SOC Term Classification Code Term Level
    8.1 10060862 Prostate cancer LLT
    Population Age: Adults, Elderly Gender: Male
    Trial protocol: LT (Completed) LV (Completed)
    Trial results: (No results available)
    EudraCT Number: 2005-004943-72 Sponsor Protocol Number: FE200486CS15A Start Date*: 2006-07-17
    Sponsor Name:Ferring Pharmaceuticals A/S
    Full Title: An Open-Label, Multi-Centre, Extension Study, evaluating the Long-Term Safety and Tolerability of Different Three-Month Degarelix Dosing Regimens, 240 mg (40 mg/mL), 240 mg (60 mg/mL), in Patients ...
    Medical condition: Prostate cancer patient
    Disease: Version SOC Term Classification Code Term Level
    7.0 10060862 pr t
    Population Age: Adults, Elderly Gender: Male
    Trial protocol: BE (Completed) FI (Completed) DE (Completed) GB (Completed) NL (Completed)
    Trial results: View results
    EudraCT Number: 2010-021900-93 Sponsor Protocol Number: CLIN1001 PCM301 Start Date*: 2010-12-14
    Sponsor Name:STEBA BIOTECH SA
    Full Title: A European randomised Phase 3 study to assess the efficacy and safety of TOOKAD® Soluble for low risk localised prostate cancer compared to Active Surveillance
    Medical condition: Low-risk prostate cancer
    Disease: Version SOC Term Classification Code Term Level
    12.1 10060862 Prostate cancer LLT
    Population Age: Adults, Elderly Gender: Male
    Trial protocol: FR (Completed) GB (Completed) DE (Completed) NL (Completed) BE (Completed) SE (Completed) FI (Completed) DK (Completed) ES (Completed) IT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2007-004349-13 Sponsor Protocol Number: ARD-0301-012 Start Date*: 2007-11-12
    Sponsor Name:Ardana Bioscience Ltd
    Full Title: A Phase II multi-centre, open-label study investigating the long-term safety and efficacy of Teverelix, long-acting formulation in patients with advanced prostate cancer – follow on study to Study ...
    Medical condition: Locally advanced and/or metastatic prostate cancer
    Disease: Version SOC Term Classification Code Term Level
    9.1 10060862 Prostate cancer LLT
    Population Age: Adults, Elderly Gender: Male
    Trial protocol: LT (Completed) LV (Completed)
    Trial results: (No results available)
    EudraCT Number: 2006-004264-31 Sponsor Protocol Number: ARD-0301-004 Start Date*: 2007-02-23
    Sponsor Name:Ardana Bioscience Ltd
    Full Title: A Phase II multi-centre, open-label study investigating the efficacy and safety of a new GnRH antagonist, Teverelix, long-acting formulation in patients with advanced prostate cancer
    Medical condition: Locally advanced and/or metastatic prostate cancer
    Disease: Version SOC Term Classification Code Term Level
    8.1 10060862 Prostate cancer LLT
    Population Age: Adults, Elderly Gender: Male
    Trial protocol: LV (Completed) LT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2016-001361-81 Sponsor Protocol Number: ICO-N-2016-01 Start Date*: 2017-02-10
    Sponsor Name:INSTITUT DE CANCEROLOGIE DE L'OUEST
    Full Title:
    Medical condition:
    Disease: Version SOC Term Classification Code Term Level
    19.1 100000004864 10036921 Prostate carcinoma LLT
    Population Age: Adults, Elderly Gender: Male
    Trial protocol: FR (Completed)
    Trial results: (No results available)
    EudraCT Number: 2006-001530-40 Sponsor Protocol Number: HEC WST06 1276N/WST 2.24 Start Date*: 2006-07-18
    Sponsor Name:STEBA FRANCE
    Full Title: Vascular targeted photodynamic therapy using WST09 for patients with untreated localised prostate cancer - Repeat procedure – Phase IIa, Single centre, open-label study.
    Medical condition: Localised Prostate Cancer
    Disease: Version SOC Term Classification Code Term Level
    10036921
    Population Age: Adults, Elderly Gender: Male
    Trial protocol: GB (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2012-004297-26 Sponsor Protocol Number: 1632/12 Start Date*: 2012-12-23
    Sponsor Name:POLICLINICO UNIVERSITARIO AGOSTINO GEMELLI
    Full Title: Phase III clinical study of PET-TC with [18f]Fluoroethyilcholine ([18f]Fech) in prostate cancer: assessment of the additional role with respec to conventional imaging techniques
    Medical condition: prostate cancer
    Disease: Version SOC Term Classification Code Term Level
    14.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10060862 Prostate cancer PT
    Population Age: Adults, Elderly Gender: Male
    Trial protocol: IT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2004-003815-22 Sponsor Protocol Number: FE200486 CS15 Start Date*: 2005-01-27
    Sponsor Name:Ferring Pharmaceuticals A/S
    Full Title: An Open-Label, Multi-Centre, Randomised Parallel Group Comparison of Efficacy and Safety of Degarelix Three-Month Depot in Three Different Dosing Regimens of 240 mg (40 mg/mL) and 240 mg (60 mg/mL)...
    Medical condition: Prostate Cancer
    Disease: Version SOC Term Classification Code Term Level
    7.0 10060862 pr t
    Population Age: Adults, Elderly Gender: Male
    Trial protocol: FI (Completed) GB (Completed)
    Trial results: View results
    EudraCT Number: 2009-009476-12 Sponsor Protocol Number: ISI 2009-01 Start Date*: 2009-07-01
    Sponsor Name:Charité Campus Mitte, Instituts für Radiologie
    Full Title: Non-invasive detection of prostate cancer using functional MRI in patients with histopathologically confirmed prostate cancer before prostatectomy
    Medical condition: Prostata cancer
    Disease: Version SOC Term Classification Code Term Level
    9.1 10007113 Cancer of prostate LLT
    Population Age: Adults, Elderly Gender: Male
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2020-003323-42 Sponsor Protocol Number: 29BRC20.0203 Start Date*: 2021-03-01
    Sponsor Name:CHRU de Brest
    Full Title: Diagnostic Performance of prostate specific membrane antigen (PSMA) positron emission tomography/computed tomography (PET/CT) imaging for Pre-operative lymph Node assessment in intermediate and hig...
    Medical condition: Prostate cancer
    Disease: Version SOC Term Classification Code Term Level
    21.0 100000004864 10036946 Prostatic cancer LLT
    Population Age: Adults, Elderly Gender: Male
    Trial protocol: FR (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2014-005345-50 Sponsor Protocol Number: RD-FCH-2014 Start Date*: 2015-04-21
    Sponsor Name:Masarykův onkologický ústav
    Full Title: Diagnostic feasibility and morfological and functional correlation of PET examination in use of [18F]-Fluorocholin inj. in patients with prostate cancer
    Medical condition: Prostate cancer
    Disease: Version SOC Term Classification Code Term Level
    17.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10060862 Prostate cancer PT
    Population Age: Adults, Elderly Gender: Male
    Trial protocol: CZ (Completed)
    Trial results: (No results available)
    EudraCT Number: 2017-001700-29 Sponsor Protocol Number: TAPS01 Start Date*: 2018-04-05
    Sponsor Name:Cambridge University Hospitals NHS Foundation Trust & The University of Cambridge
    Full Title: Targeted drug intervention to inhibit cancer progression in men on active surveillance for prostate cancer. Therapeutics in Active Prostate cancer Surveillance (TAPS01)
    Medical condition: Prostate cancer, managed by active surveillance - low or intermediate risk according to NICE classification and an MRI score of ≥ 3 for lesion probability using PIRAD version 2 reporting criteria.
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10060862 Prostate cancer PT
    Population Age: Adults, Elderly Gender: Male
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2017-002276-37 Sponsor Protocol Number: AK-2017-PC-1 Start Date*: 2017-08-25
    Sponsor Name:Rigshospitalet, Department of Clinical Physiology, Nuclear Medicine & PET
    Full Title: Phase II trial: uPAR-PET/MR in patients with newly diagnosed prostate cancer; non-invasive characterization of tumor aggressiveness
    Medical condition: Prostate cancer
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10060862 Prostate cancer PT
    Population Age: Adults, Elderly Gender: Male
    Trial protocol: DK (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2018-001036-21 Sponsor Protocol Number: PCaRestaging-PET/MR Start Date*: 2020-03-04
    Sponsor Name:OSPEDALE SAN RAFFAELE
    Full Title: Phase II monocentric study on prostate cancer restaging using PET/MR with innovative radiotracers
    Medical condition: Radically treated patient for prostate cancer presenting a biochemical recurrence of disease (PSA: > o = 0.2 ng/mL)
    Disease: Version SOC Term Classification Code Term Level
    21.1 100000004864 10026389 Malignant neoplasm of prostate LLT
    Population Age: Adults, Elderly Gender: Male
    Trial protocol: IT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2006-001511-30 Sponsor Protocol Number: 2-55-52014-145 Start Date*: 2006-10-26
    Sponsor Name:Beaufour Ipsen Pharma
    Full Title: A phase III, single arm, multicentre study to evaluate the efficacy and safety of a subcutaneous four-month sustained-release formulation of triptorelin, a gonadotrophin releasing hormone analogue ...
    Medical condition: Locally advanced or metastatic prostate cancer
    Disease: Version SOC Term Classification Code Term Level
    8.1 10060862 Prostate cancer PT
    Population Age: Adults, Elderly Gender: Male
    Trial protocol: BE (Completed) GB (Prematurely Ended) FR (Completed) PT (Completed) LV (Prematurely Ended) LT (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2012-005665-12 Sponsor Protocol Number: MDV3100-14(C3431005) Start Date*: 2013-09-06
    Sponsor Name:Medivation, Inc., a wholly owned subsidiary of Pfizer Inc.
    Full Title: A Multinational, Phase 3, Randomized, Double Blind, Placebo Controlled, Efficacy and Safety Study of Enzalutamide in Patients With Nonmetastatic Castration Resistant Prostate Cancer
    Medical condition: Patients With Nonmetastatic Castration Resistant Prostate Cancer
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10060862 Prostate cancer PT
    Population Age: Adults, Elderly Gender: Male
    Trial protocol: SE (Completed) IT (Completed) AT (Completed) BE (Completed) GB (GB - no longer in EU/EEA) SK (Completed) FI (Completed) NL (Completed) ES (Completed) GR (Completed) FR (Completed) DK (Completed) DE (Completed)
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    « Previous 1  2  3  4  5  6  7  8  9  Next» Last»»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Thu Jun 05 22:43:56 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA